Furthermore, we also observed statistically significant association of tumor BRCA1 and BRCA2 mutations with OS (BRCA1: adjusted HR 1.50, 95% CI 1.16 to 1.93, P = 0.079; BRCA2:adjusted HR 1.50, 95% CI 1.03 to 2.19, P = 0.079), but not with BCSS or EFS in breast cancer patients (Supplementary Table S1) using trim and filled method to test the internal validity, which was consistent with the primary analyses. This evidence concerns the gene BRCA2 and neoplasm.